Medication therapy management and adherence among US renal transplant recipients

Patient Preference and Adherence

Volumn 10, Issue , 2016, Pages 703-709

  Chisholm Burns, Marie A ^a   Spivey, Christina A ^a   Tolley, Elizabeth A ^b   Kaplan, Erin K ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Medicare Part D; Medication adherence; Medication therapy management; Renal transplant

Indexed keywords

TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HEALTH SERVICE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; MEDICAID; MEDICARE; MEDICATION COMPLIANCE; MEDICATION THERAPY MANAGEMENT; PRESCRIPTION; UNITED STATES;

EID: 84968853454     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S104646     Document Type: Article

References (30)

1. Pinsky BW, Takemoto SK, Lentine KL, Burroughs TE, Schnitzler MA, Salvalaggio PR. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant. 2009;9:2597–2606.
2. Spivey CA, Chisholm-Burns MA, Damadzadeh B, Billheimer D. Determining the effect of immunosuppressant adherence on graft failure risk among renal transplant recipients. Clin Transplant. 2014;28:96–104.
3. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77:769–776.
4. Denhaerynck K, Dobbels F, Cleemput I, et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int. 2005;18:1121–1133.
5. Chisholm MA, Lance CE, Williamson GM, Mulloy LL. Development and validation of an immunosuppressant therapy adherence barrier instrument. Nephrol Dial Transplant. 2005;20:181–188.
6. Chisholm MA, Mulloy LL, DiPiro JT. Comparing renal transplant patients’ adherence to free cyclosporine and free tacrolimus immunosuppressant therapy. Clin Transplant. 2005;19:77–82.
7. Viswanathan M, Kahwati LC, Golin CE, et al. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med. 2015;175:76–87.
8. Wang J, Qiao Y, Shih Y-CT, et al. Effects of Medicare Part D on disparity implications of medication therapy management eligibility criteria. Am Health Drug Benefits. 2014;7(6):346–358.
9. American Pharmacists Association. APhA MTM Central. What is medication therapy management? Available from: http://www.pharmacist.com/mtm. Accessed August 19, 2015.
10. Medication Therapy Management in Pharmacy Practice: Core Elements of an MTM Service Model. Version 2.0; 2008. Available from: http://www.pharmacist.com/sites/default/files/files/core_elements_of_an_mtm_practice.pdf. Accessed November 17, 2015.
11. Thumar R, Zaiken K. Impact of live medication therapy management on cholesterol values in patients with cardiovascular disease. J Am Pharm Assoc. 2014;54:526–529.
12. Planas LG, Crosby KM, Mitchell KD, Farmer KC. Evaluation of a hypertension medication therapy management program in patients with diabetes. J Am Pharm Assoc. 2009;49:164–170.
13. Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best BM. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm. 2011;17(3):213–223.
14. Moore JM, Shartle D, Faudskar L, Matlin OS, Brennan TA. Impact of a patient-centered pharmacy program and intervention in a high-risk group. J Manag Care Pharm. 2013;19(3):228–236.
15. Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Impact of clinical pharmacy services on renal transplant patients’ compliance with immunosuppressive medications. Clin Transplant. 2001;15: 330–336.
16. Centers of Medicare and Medicaid Services. Medication therapy management. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/MTM.html. Accessed August 17, 2015.
17. Medicare Part D Medication Therapy Management (MTM) Programs 2009 Fact Sheet; 2009. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/downloads/MTMFactSheet_2009_06-2009_fnl.pdf. Accessed August 17, 2015.
18. Medicare Part D Medication Therapy Management (MTM) Programs. Fact sheet; 2010. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/downloads/MTMFactSheet_2010_06-2010_final.pdf. Accessed August 17, 2015.
19. Centers for Medicare and Medicaid Services. Chronic conditions. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Chronic-Conditions/CC_Main.html. Accessed August 19, 2015.
20. Daniel GW, Malone DC. Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare medication therapy management programs. J Manag Care Pharm. 2007;13(2):142–154.
21. Watanabe JH, Kazerooni R, Bounthavong M. Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study. J Manag Care Pharm. 2014;20: 43–50.
22. Watanabe JH, Bounthavong M, Chen T, Ney JP. Association of polypharmacy and statin new-user adherence in a Veterans Health Administration population: a retrospective cohort study. Ann Pharmacother. 2013;47:1253–1259.
23. Skinner JS, Poe B, Hopper R, Boyer A, Wilkins CH. Assessing the effectiveness of pharmacist-directed medication therapy management in improving diabetes outcomes in patients with poorly controlled diabetes. Diabetes Educ. 2015;41:459–465.
24. Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006;6:48.
25. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521–530.
26. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
27. New England Healthcare Institute. Thinking outside the pillbox. A system-wide approach to improving patient medication adherence for chronic disease. New England Healthcare Institute Research Brief; 2009. Available from: http://www.nehi.net/publications/17-thinking-outside-the-pillbox-a-system-wide-approach-to-improving-patient-medication-adherence-for-chronic-disease/view. Accessed November 17, 2015.
28. Wang J, Shih YC, Qin Y, et al. Trends in Medicare Part D medication therapy management eligibility criteria. Am Health Drug Benefits. 2015;8(5):247–255.
29. Wang J, Zhang Z, Spivey CA, Chisholm-Burns M. Historical trend of racial and ethnic disparities in meeting Medicare medication therapy management eligibility in non-Medicare population. Res Social Adm Pharm. 2014;10:904–917.
30. Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95:333–340.